Molecular Imaging Program, National Cancer Institute, National Institute of Health (NIH), Bethesda, Maryland.
JAMA Oncol. 2017 Oct 1;3(10):1415-1422. doi: 10.1001/jamaoncol.2016.5840.
Prostate cancer is the second leading cause of cancer deaths in US men. The course of prostate cancer is highly variable, and timely and accurate detection of clinically significant cancer is critical in positively affecting outcomes.
Molecular imaging methods and magnetic resonance imaging (MRI) are the most promising new developments for prostate tumor visualization. While the benefits of MRI are many, positron emission tomography (PET) radiotracers are still available only as research tools.
The current research-based evidence on PET imaging has demonstrated encouraging potential in the initial diagnosis and detection of recurrence and metastases of prostate cancer.
前列腺癌是美国男性癌症死亡的第二大主要原因。前列腺癌的病程变化多端，及时准确地检测出具有临床意义的癌症对于改善预后至关重要。
分子成像方法和磁共振成像（MRI）是前列腺肿瘤可视化最有前途的新进展。虽然 MRI 有很多优势，但正电子发射断层扫描（PET）放射性示踪剂仍然只能作为研究工具使用。
目前基于研究的 PET 成像证据在前列腺癌的初始诊断、复发和转移的检测方面显示出了令人鼓舞的潜力。
